Chlorpyrifos has undergone dramatic changes in its market trajectory, from a blockbuster proprietary molecule to a globally traded generic active ingredient. AgriBusiness Global spoke with Ram ...

President Donald Trump has been successful in convincing many of the world’s top drugmakers to commit to manufacturing more of their prescription treatments in the U.S. But what about the onshoring of ...

Google today released its 2025 Year in Search list, but don’t mistake it for a ranking of the “top searches” or the “most searched” terms. This year’s recap focused on trending queries – the topics ...

After primarily focusing on private conversations since its founding, Snapchat is embracing public conversations with a new “Topic Chats” feature. The social network says the feature lets users chat ...

Out Of Order is a Java-based interactive game designed to test and improve the player's cognitive abilities. In this game, players are presented with a sequence of characters or numbers that are out ...

java-core project provides vast interview programs, Real time implementation, Exceptions, regular expressions, collections, oops concepts ect. Here you can gain the knowledge about java syntax, ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

President Trump said he expects to reach pricing deals with more drug companies following the Pfizer announcement. Photo: Win McNamee/Getty Images WASHINGTON—The Trump administration said it isn’t ...

Gilead Sciences, Inc. (NASDAQ:GILD) on Monday entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed ...

Technological advancement has become a leading cause of economic growth and global influence. The innovation nations, research nations, and technologically advanced nations are setting the future ...

Against a backdrop of tariff updates and a drug pricing deal from the Trump administration, the FDA charted a pair of moves this week in its push to make drug manufacturing more attractive in the U.S.